Catalogo dei prodotti della ricerca

MILLEFIORINI, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.666
EU - Europa 988
AS - Asia 517
SA - Sud America 20
AF - Africa 9
OC - Oceania 4
Totale 5.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.640
IT - Italia 321
SG - Singapore 204
SE - Svezia 191
IN - India 175
UA - Ucraina 128
CN - Cina 124
FI - Finlandia 115
DE - Germania 102
GB - Regno Unito 28
BG - Bulgaria 25
CA - Canada 20
AR - Argentina 17
IE - Irlanda 14
RU - Federazione Russa 14
RO - Romania 12
BE - Belgio 9
CZ - Repubblica Ceca 6
MX - Messico 5
AU - Australia 4
FR - Francia 4
HK - Hong Kong 4
NL - Olanda 4
TG - Togo 4
CH - Svizzera 3
MK - Macedonia 3
DZ - Algeria 2
ES - Italia 2
GR - Grecia 2
IL - Israele 2
IR - Iran 2
LT - Lituania 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BR - Brasile 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
IQ - Iraq 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 5.204
Salva come PNG Salva come JPEG
Città #
Fairfield 609
Woodbridge 355
Ashburn 285
Chandler 230
Seattle 229
Houston 210
Wilmington 197
Cambridge 190
Ann Arbor 145
Singapore 145
Princeton 117
Rome 110
Plano 85
Dearborn 79
San Paolo di Civitate 73
Beijing 65
Lawrence 60
Boston 57
Des Moines 50
Jacksonville 48
San Diego 41
Helsinki 36
Norwalk 30
Andover 26
Millbury 25
Sofia 25
New York 20
Federal 17
Boardman 16
Dublin 14
Santa Clara 14
Milan 13
Toronto 13
Falls Church 12
Fasano 12
Brussels 9
Bühl 9
Hefei 8
Nanjing 8
Fremont 7
Grafing 7
Brno 6
Auburn Hills 5
Indiana 5
San Mateo 5
Bari 4
Hong Kong 4
Jinan 4
Lomé 4
Mannheim 4
Mexico City 4
Nanchang 4
Ottawa 4
Phoenix 4
Venezia 4
Albano Laziale 3
London 3
Martellago 3
Salerno 3
Sheffield 3
Skopje 3
Stockholm 3
Turin 3
Zhengzhou 3
Algiers 2
Bern 2
Bonndorf 2
Catania 2
Conegliano 2
Fuzhou 2
Guangzhou 2
Hyderabad 2
Jerusalem 2
Kunming 2
Laurel 2
Marigliano 2
Montréal 2
Morlupo 2
Mountain View 2
Munich 2
Newark 2
Oakland 2
Oyster Bay 2
Philadelphia 2
Pomezia 2
Sezze 2
Shanghai 2
Silverton 2
Southend 2
Staten Island 2
Taiyuan 2
Taranto 2
Thessaloniki 2
Tower Hamlets 2
Washington 2
Alabaster 1
Altea 1
Amsterdam 1
Arnsberg 1
Atina 1
Totale 3.856
Salva come PNG Salva come JPEG
Nome #
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis 107
Deep grey matter involvement and altered sensory gating in multiple sclerosis 106
Mechanisms of pain in multiple sclerosis: A combined clinical and neurophysiological study 104
Lead poisoning during heroin addiction 101
Computerized color perimetry in multiple sclerosis 100
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 100
Increased circulating levels of vitamin D binding protein in MS patients 95
Involvement of the limbic system in multiple sclerosis patients with depressive disorders 91
Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis - Results of the BetaPlus observational cohort study 85
Trigeminal neuralgia and pain related to multiple sclerosis. 84
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. 83
Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. 83
Campimetria cromatica nella sclerosi multipla 81
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis. An Italian, Multicenter, Real-World Study 81
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 79
Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. 79
Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. 78
A controlled study of potential risk factors preceding exacerbation in multiple sclerosis. 78
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 78
La neurologia della Sapienza 77
BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS 77
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 76
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment 76
Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation 72
Mitochondrial Genome Profile in Demyelinating Diseases 71
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by rebiject autoinjection over a 1-year period: The CoSa study 70
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 70
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 70
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases 70
Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study 69
Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. 68
Circadian variation in the onset of acute cerebral ischemia: ethiopathogenetic correlates in 80 patients given angiography. 68
Photophobia in multiple sclerosis 68
Fingolimod vs dimethyl fumarate in multiple sclerosis. a real-world propensity score-matched study 67
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 66
Expression of biomarkers of interferon type I in patients suffering from chronic diseases 65
An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis 65
Fatigue in MS is associated with specific clinical features. 64
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. 63
Involvement of the limbic system in multiple sclerosis patients with depressive disorders. 62
Influenza immunization in multiple sclerosis 61
null 60
Effect of stress on cardiovascular regulation in neurological diseases with dysautonomia. 59
Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis 58
Brain atrophy in relasping-remitting multiple sclerosis:relationship with "black holes", disease duration and disability 57
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 57
Interferon beta-1a in relapsing-remitting multiple sclerosis:effect on hypointense lesion volume on T1-weighted images 57
Cardiac autonomic dysfunction in relapsing-remitting multiple sclerosis during a stable phase 57
null 57
Invasive treatment of acute stroke. 56
FATIGUE IN MS IS ASSOCIATED WITH SPECIFIC CLINICAL-FEATURES 55
Proteolytic balance in patients with multiple sclerosis during interferon treatment 53
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS 53
Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers 51
Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study 51
null 49
INVASIVE TREATMENT OF ACUTE STROKE 49
null 49
The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. 48
Lack of association between macrocytosis and multiple sclerosis. 48
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 46
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 46
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 46
null 45
Subclinical peripheral nervous system involvement in multiple sclerosis 44
Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis 44
Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis: A Pilot Study 44
Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. 43
the prevalence of ms in central italy 42
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 42
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients 41
ccl2 induction by 1,25 (oh)2d3 in debdritic cells from healty donors and ms patients 39
Evolution and severity markers in 233 MS patients. 39
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 39
Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. 37
A longitudinal study in multiple sclerosis 35
null 33
short-term brain atrophy changes in r-r multiple sclerosis 31
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 30
Fattori prognostici in pazienti con sclerosi multipla di tipo recidivante-remittente. Studio longitudinale di 3 anni. 30
Controlled clinical trials in stroke. 29
Possibile ruolo delle infezioni virali nell’eziopatogenesi della sclerosi multipla: indagine su un gruppo di pazienti con SM remittente 29
Sclerosi Multipla 27
Opposite regulatory effects of IFN-β and IL-3 on C-type lectin receptors, antigen uptake, and phagocytosis in human macrophages 24
Subclinical peripheral nervous system involvement in multiple sclerosis. 23
Viral infections and multiple sclerosis: research on remittent-relapsing MS patients. 23
Prognosi precoce nella paralisi di Bell in base a rilievi clinico neurofisiologici standardizzati 22
Prognostic indicators in pediatric clinically isolated syndrome 21
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 19
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 19
natalizumab therapy of ms study group 17
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 16
Somatosensory temporal discrimination threshold is impaired in patients with multiple sclerosis 15
the global adherence project a multicenter observation study on adherence to disease-modifying therapies in patients with rr-ma. 14
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 14
Intradetrusorial botulinum toxin in patients with multiple sclerosis: A neurophysiological study 12
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 10
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 9
OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results 2
Totale 5.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.061 0 0 0 64 133 183 175 159 141 104 68 34
2020/2021448 47 49 21 37 4 29 33 42 41 97 38 10
2021/20221.002 6 58 77 45 143 42 26 101 70 79 166 189
2022/2023978 219 197 49 74 93 117 31 45 99 5 40 9
2023/2024427 20 54 17 24 36 53 19 40 2 52 52 58
2024/2025223 59 84 67 13 0 0 0 0 0 0 0 0
Totale 5.373